EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors

Irene Hernández de Córdoba Sánchez, Mercedes Avedillo Ruidiaz, Victor Moreno, Henry Long, Paloma Cejas

Cancer Treatment Reviews · 2026

DOI: 10.1016/j.ctrv.2026.103145 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026. Verfasst von Irene Hernández de Córdoba Sánchez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Hospital Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, Spain. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Neoplasms, Epigenesis, Genetic, Protein-Arginine N-Methyltransferases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 99 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinNeoplasmsEpigenesis, GeneticProtein-Arginine N-MethyltransferasesAntineoplastic AgentsHumansBromodomain Containing ProteinsMolecular Targeted TherapyAnimalsProteins

Stichwörter der Autor:innen

BET inhibitorsChromatin remodelingEZH2 inhibitorsEpigenetic therapyPRMT5 inhibitorsSolid tumors

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanProtein-Arginine N-MethyltransferasesPRMT5 protein, humanAntineoplastic AgentsBromodomain Containing Proteinsbromodomain and extra-terminal domain protein, humanProteins

Autor:innen und Institutionen

  • Department of Medical Oncology, University Hospital Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, Spain.
  • Department of Medical Oncology, University Hospital Fundación Jiménez Díaz, Moncloa-Aravaca, 28040 Madrid, Spain.
  • START Madrid-FJD Early Phase Clinical Trials Unit, University Hospital Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: paloma_cejas@dfci.harvard.edu.

Zitieren

APA

de Córdoba Sánchez, I. H., Ruidiaz, M. A., Moreno, V., Long, H., & Cejas, P. (2026). Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2026.103145

Vancouver

de Córdoba Sánchez IH, Ruidiaz MA, Moreno V, Long H, Cejas P. Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors. Cancer Treatment Reviews. 2026. doi:10.1016/j.ctrv.2026.103145

BibTeX
@article{deCrdobaSnchez2026,
  author = {de Córdoba Sánchez, Irene Hernández and Ruidiaz, Mercedes Avedillo and Moreno, Victor and Long, Henry and Cejas, Paloma},
  title = {Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  doi = {10.1016/j.ctrv.2026.103145}
}
Kostenlos starten →